Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Is
Total Page:16
File Type:pdf, Size:1020Kb
Diabetes Page 2 of 61 Carboxyl-ester lipase Maturity-Onset Diabetes of the Young is Associated with Development of Pancreatic Cysts and Upregulated MAPK Signaling in Secretin- stimulated duodenal fluid Helge Ræder 1,2,3, Fiona E. McAllister4*, Erling Tjora2,3*, Shweta Bhatt1, Ingfrid Haldorsen5,6, Jiang Hu1, Stefan M. Willems4, Mette Vesterhus7, Abdelfattah El Ouaamari1, Manway Liu8, Maria B. Raeder3, Heike Immervoll9,10,11, Dag Hoem12, Georg Dimcevski7 , Pål R. Njolstad2,3, Anders Molven9,10, Steven P Gygi4, Rohit N. Kulkarni1 From the 1Section of Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA, 2Department of Pediatrics, Haukeland University Hospital, Bergen, Norway; 3Department of Clinical Science, University of Bergen, Bergen, Norway, 4Department of Cell Biology, Harvard Medical School, Boston, MA, USA,5Department of Radiology, Haukeland University Hospital, Bergen, Norway; 6Section for Radiology, Department of Clinical Medicine, University of Bergen, 7Department of Medicine, Haukeland University Hospital, Bergen, Norway, 8Department of Biomedical Engineering, Boston University, Boston, MA,USA , 9The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Norway; 10Department of Pathology, Haukeland University Hospital, Bergen, Norway, 11Department of Pathology, Ålesund Hospital, Ålesund, Norway; 12Department of Surgery, Haukeland University Hospital, Bergen, Norway, *,These authors contributed equally. Corresponding author: Helge Raeder, [email protected] 1 Diabetes Publish Ahead of Print, published online September 23, 2013 Page 3 of 61 Diabetes Running title: PANCREATIC CYSTS AND MAPK SIGNALING IN CEL-MODY Original article: Word count, abstract: 200, Word count, main text: 3161, Number of references: 33, Number of figures: 5, Number of tables: 2. ABSTRACT CEL-MODY is a monogenic form of diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl-ester lipase gene CEL. The pathogenic mechanism for diabetes development is unknown. Since CEL is expressed mainly in pancreatic acinar cells, we asked whether we could find structural pancreatic changes in CEL-MODY subjects during the course of diabetes development. Furthermore, we hypotesized that the diseased pancreas releases proteins which are detectable in pancreatic fluid and potentially reflected activation or inactivation of disease-specific pathways. We therefore investigated non-diabetic and diabetic CEL mutation carriers by pancreatic imaging studies and secretin-stimulated duodenal juice sampling. The secretin-stimulated duodenal juice was studied using cytokine assays, triple-stage mass spectrometry (MS3) and multiplexed mass spectrometry-based measurement of kinase activities. We identified multiple pancreatic cysts in all the eight diabetic mutation carriers but not in any of the four non-diabetic mutation carriers or the six healthy controls. Furthermore, we identified upregulated MAPK target proteins and MAPK-driven cytokines and increased MAPK activity in the secretin-stimulated duodenal juice. These findings show that subjects with CEL- MODY develop multiple pancreatic cysts by the time they develop diabetes and that upregulated MAPK signaling in the pancreatic secretome may reflect the pathophysiological development of pancreatic cysts and diabetes. Keywords: MODY; Carboxyl-ester lipase, pancreatic cysts, proteome profiling; MAPK signaling 2 Diabetes Page 4 of 61 INTRODUCTION Studies of patients with Maturity-onset Diabetes of the Young have provided important insight into disease mechanisms of pancreatic beta cell failure and diabetes development and also contributed to novel treatment strategies based on this insight (1; 2). We have previously reported two families with a human monogenic syndrome of diabetes and pancreatic exocrine dysfunction (maturity-onset diabetes of the young, type 8, MODY8; CEL-MODY;OMIM #609812) caused by mutations in the carboxyl-ester lipase (CEL) gene (3). Patients with CEL mutations develop pancreatic exocrine dysfunction in early childhood (as measured by low fecal elastase levels), accumulate pancreatic fatty tissue, and develop diabetes and clinical malabsorption in their fourth decade of life (3; 4). The CEL gene is primarily expressed in pancreatic acinar cells and lactating mammary tissue, and encodes a digestive enzyme with a role in cholesterol ester digestion (5). Studies of animal models have not been able to explain the disease mechanism of diabetes development in CEL-MODY (6; 7), but cellular studies indicate that mutated CEL protein is misfolded (8). Hence, to gain further insight into the disease mechanism, we further studied human CEL mutation carriers using radiological methods and secretin-stimulated duodenal juice to examine the pancreatic proteome (9). We hypotesized that the diseased pancreas releases proteins which are detectable in pancreatic fluid and potentially reflected activation or inactivation of disease-specific pathways. To optimize the accuracy of the proteomics studies we applied triple-stage mass spectrometry, MS3 (10), and complemented this approach with cytokine assays and MS-based multiplex kinase activity assays (11) to cross-validate our findings. 3 Page 5 of 61 Diabetes RESEARCH DESIGN AND METHODS Patients. We have previously reported various clinical characteristics for the CEL mutation carrying subjects (3). In this study the studied CEL mutation carrying subjects (CEL+) were denoted with the prefix D if they had manifest diabetes (D1, D2, D3 and D4), with the prefix P if they had not yet developed diabetes (P1 or P2), or with the prefix C for the patient with pancreatic ductal adenocarcinoma (C1). The Supplemental Online Appendix contains the corresponding pedigree information. The non-family controls were denoted with the prefix N (N1, N2, N3, N4) for controls in the duodenal juice studies. We sampled duodenal juice from the patients by endoscopy. To enrich for pancreatic factors, we administered intravenous secretin ((Secrelux® Sanofi, Germany. 1 cU/kg, max 70 cU) to the patients and sampled duodenal juice from 30 to 45 minutes later since it has been shown that there is a peak secretion from pancreas in this time interval (12; 13). The controls for the secretin-stimulated duodenal juice studies were recruited from volunteers. The single pancreatic juice specimen from a CEL mutation carrier with PDAC was collected during a classical Whipple procedure. All studies were approved by the Norwegian regional committee for research ethics and the IRB at the Joslin Diabetes Center and performed according to the Helsinki Declaration. We obtained written informed consent from subjects or their parents. Patients were of North-European descent and recruited from the Norwegian MODY Registry. Protocol for pancreatic imaging. MR imaging was performed on a 1.5 T Siemens Avanto running Syngo MR B17 (Erlagen, Germany) using a 12-channel body coil. For clinical and anatomical evaluation of the pancreas a standard abdominal protocol was used: Axial TrueFISP (true Fast Imaging with Steady-state Precision; TR (repetition time) = 2.79 ms, TE (echo time) = 1.17 ms, slice thickness = 4.0 mm, spacing = 0, alfa = 63 degrees, FOV (field of view) = 380 mm x 380 mm, matrix = 156 x 192, acquisition time = 15 s) and axial fat-saturated T2-weighted 4 Diabetes Page 6 of 61 imaging (TR = 1000 ms, TE (echo time) = 90 ms, slice thickness = 5 mm, spacing = 0, alfa = 150 degrees, FOV (field of view) = 350 mm x 350 mm, matrix = 256 x 256, acquisition time = 24 s). For evaluation of the pancreatic and biliary ducts magnetic resonance cholangiopancreaticography (MRCP) was performed: Coronal T2-weigthed imaging (TR = 2000 ms, TE (echo time) = 691 ms, slice thickness = 1.1 mm, spacing = 0, alfa = 140 degrees, FOV (field of view) = 280 mm x 280 mm, matrix = 320 x 320, acquisition time = 5.23 min) with maximum intensity projection (MIP) and multiplanar reformatting (MPR). Cytokine assay. Forty-two cytokines were measured in secretin-stimulated duodenal juice samples (sample volume of 25 microliter), using the MILLIPLEX MAP Human Cytokine/Chemokine - Premixed 42 Plex kit from Millipore (Billerica, MA). This 42-plex kit was used to measure the concentrations of EGF, Eotaxin, FGF-2, Flt-3 ligand, Fractalkine, G- CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL- 1Rα, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGF-α, TNF-α, TNF-β, VEGF, sCD40L, sIL-2Rα. All samples were analyzed with a Luminex 200 xMAP system, and MILLIPLEX Analyst Software (VigeneTech, Carlisle, MA) was used to analyse the results. Proteolytic degradation assay. A set of 45 synthetic peptide substrates, each at 1 µM, were incubated with 10 µg pancreatic fluid and reaction buffer containing Tris-Cl (25 mM, pH 7.5), MgCl2 (7.5 mM), EGTA (0.2 mM), β-glycerophosphate (7.5 mM), Na3VO4 (0.1 mM) and DTT (0.1 mM). The reaction was incubated at room temperature for 0, 15, 60 min, after which the reaction was quenched with 100 µL of 1% trifluoroacetic acid (TFA). Twenty five pmol of internal standard stable-isotope labeled substrate peptides was spiked into the quenched reaction. The solution was desalted using Sep-Pak C18 50 mg cartridges (Waters) and dried using vacuum 5 Page 7 of 61 Diabetes centrifugation. The desalted sample was then resuspended in 100 µL of 5% formic acid of which 2 µL was then subjected to analysis by mass spectrometry. Technical duplicates were performed for each sample at each time point. The peptides from proteolytic degradation assays were analysed by LC-MS on a high resolution Exactive Orbitrap mass spectrometer (Thermo). Briefly, a 45 minute gradient was used to separate the peptides from 10-37% solvent B (0.125% formic acid in acentonitrile) at a flow rate of 300 mL/min. LC-MS data was collected from 350-1500 m/z and the extracted ion chromatograms of the light and heavy peptides were used to quantitate the absolute kinase activity and the extent of peptide degradation respectively. Data analysis was performed using Pinpoint (Thermo).